Xenetic Biosciences is a biopharmaceutical company developing next-generation biologic drugs and novel oncology therapeutics. Xenetic's proprietary drug technology platforms include PolyXen® for the development of next generation biologic drugs that extend the efficacy, safety and half-life of biologic drugs and OncoHist® for the development of novel oncology drugs focused on orphan indications.
Xenetic is developing a biopharmaceutical pipeline with a multi-billion dollar market potential.
Xenetic has collaborations with leading global biopharma companies, including Baxter International
Jan 16, 2015
Xenetic Biosciences Completes Enrollment of Second Cohort in Phase 2a Study with ErepoXen® for Anemia; Hemoglobin Levels Rise into Therapeutic Range over Time